Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections - Are they applicable today?

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 6, 2008, Pages 9-18

  Cainzos M ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Complicated intra abdominal infections; Complicated skin and soft tissue infection; Novel antimicrobials; Resistant pathogens; Treatment guidelines

Indexed keywords

ANTIINFECTIVE AGENT; CEFAZOLIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; CONFERENCE PAPER; DRUG CHOICE; ESCHERICHIA COLI; HIGH RISK PATIENT; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SKIN INCISION; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL INFECTION; SURGICAL PATIENT; SURGICAL SITE INFECTION; SURGICAL TECHNIQUE;

BACTEROIDES FRAGILIS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA;

EID: 56849102517     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02123.x     Document Type: Conference Paper

References (41)

1. Astagneau P, Rioux C, Golliot F, Brucker G. Morbidity and mortality associated with surgical site infections: Results from the 1997-1999 INCISO surveillance. J Hosp Infect 2001; 48: 267-274.
2. Seguin P, Laviolle B, Chanavaz C et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy. Clin Microbiol Infect 2006; 12: 980-985.
3. Sturkenboom MC, Goettsch WG, Picelli G et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005; 60: 438-443.
4. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
5. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44(suppl A): 19-23.
6. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001; 14: 244-269.
7. Marshall JC. Intra-abdominal infections. Microbes Infect 2004; 6: 1015-1025.
8. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-1171.
9. Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002; 43: 303-309.
10. Elston DM. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol. 2007; 56: 1-16; quiz 7-20.
11. Leaper DJ, van Goor H, Reilly J et al. Surgical site infection-a European perspective of incidence and economic burden. Int Wound J 2004; 1: 247-273.
12. Summanen PH, Talan DA, Strong C et al. Bacteriology of skin and soft-tissue infections: Comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin Infect Dis 1995; 20(suppl 2): S279-S282.
13. Mazuski JE, Sawyer RG, Nathens AB et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt). 2002; 3: 175-233.
14. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-1406.
15. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999; 20: 250-278; quiz 79-80.
16. Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical site infection (SSI) rates in the United States, 1992-1998: The National Nosocomial Infections Surveillance System basic SSI risk index. Clin Infect Dis 2001; 33(suppl 2): S69-S77.
17. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12(suppl 1): 16-23.
18. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-208.
19. Weigel LM, Donlan RM, Shin DH et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007; 51: 231-238.
20. Mariani PG, Sader HS, Jones RN. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006; 58: 481-483.
21. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42: 1652-1653.
22. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44: 655-656.
23. Roberts SM, Freeman AF, Harrington SM, Holland SM, Murray PR, Zelazny AM. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006; 25: 562-564.
24. Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006; 27: 300-302.
25. Pacelli F, Doglietto GB, Alfieri S et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996; 131: 641-645.
26. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
27. Krobot K, Yin D, Zhang Q et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23: 682-687.
28. Bare M, Castells X, Garcia A, Riu M, Comas M, Egea MJ. Importance of appropriateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections. Int J Technol Assess Health Care. 2006; 22: 242-248.
29. Barie PS. Management of complicated intra-abdominal infections. J Chemother 1999; 11: 464-477.
30. Laroche M, Harding G. Primary and secondary peritonitis: An update. Eur J Clin Microbiol Infect Dis 1998; 17: 542-550.
31. Roehrborn A, Thomas L, Potreck O et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001; 33: 1513-1519.
32. Cainzos M, Vidal B, Garcia-Riestra C, Mena E, Potel J. Surgical site infections: Microbiology. Eur Surg Res 2005; 37(suppl 1): 55-56.
33. Mazuski JE, Sawyer RG, Nathens AB et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect (Larchmt). 2002; 3: 161-173.
34. Powers JH. Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis 2004; 39(suppl 4): S228-S235.
35. Eliopoulos GM, Eliopoulos CT. Antibiotic combinations: Should they be tested? Clin Microbiol Rev 1988; 1: 139-156.
36. Davey PG, Vacani P, Parker SE, Malek MM. Assessing cost effectiveness of antimicrobial treatment: Monotherapy compared with combination therapy. Eur J Surg Suppl 1994; (573): 67-72.
37. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36: 592-598.
38. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-4581.
39. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-174.
40. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
41. Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroids fragilis group: Report and analysis of trends in the United States for 1997-2004. Antimicrob Agents Chemother 2007; 51: 1649-1655.